Publications by authors named "See Phan"


Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.

J Clin Oncol 2017 Feb 12;35(4):412-420. Epub 2016 Dec 12.

David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China.

View Article and Find Full Text PDF
February 2017

The impact of mid-treatment MRI on defining boost volumes in the radiation treatment of glioblastoma multiforme.

Technol Cancer Res Treat 2004 Jun;3(3):303-7

University of Wisconsin, Department of Radiation Oncology, K4/B100, 600 Highland Ave, Madison, WI 53792, USA.

View Article and Find Full Text PDF
June 2004